STOCK TITAN
  1. Home
  2. Sec-filings
  3. GNPX
  4. [Form 4] Genprex, Inc. Insider Trading Activity

Genprex (GNPX) CEO Ryan Confer reports 45,000 RSUs award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Genprex, Inc. reported that its President, CEO and CFO, Ryan Confer, received an award of 45,000 restricted stock units (RSUs) of common stock on December 22, 2025 under the company’s 2018 Equity Incentive Plan. These RSUs vest in two equal installments of 50% on February 27, 2026 and 50% on February 27, 2027, if he continues to serve as a service provider through each vesting date. Each vested RSU will be settled in one share of Genprex common stock. Following this grant and giving effect to Genprex’s 1-for-50 reverse stock split effective as of October 21, 2025, Confer beneficially owns 45,661 shares of Genprex common stock in total.

Positive

  • None.

Negative

  • None.
Insider Confer Ryan M.
Role President, CEO and CFO
Type Security Shares Price Value
Grant/Award Common Stock 45,000 $0.00 --
Holdings After Transaction: Common Stock — 45,661 shares (Direct)
Footnotes (1)
  1. This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests in installments of 50% on February 27, 2026 and the remaining 50% on February 27, 2027, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting dates. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Confer Ryan M.
(Last) (First) (Middle)
3300 BEE CAVE ROAD
#650-227
(Street)
AUSTIN TX 78746
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Genprex, Inc. [ GNPX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President, CEO and CFO
3. Date of Earliest Transaction (Month/Day/Year)
12/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/22/2025 A 45,000(1) A $0 45,661(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests in installments of 50% on February 27, 2026 and the remaining 50% on February 27, 2027, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting dates. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.
2. This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025.
/s/ Ryan Confer 12/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Genprex (GNPX) report for Ryan Confer?

Genprex reported that President, CEO and CFO Ryan Confer received an award of 45,000 restricted stock units (RSUs) of the company’s common stock on December 22, 2025.

How do the 45,000 RSUs granted to Genprex (GNPX) CEO vest?

The 45,000 RSUs vest in two equal installments: 50% on February 27, 2026 and the remaining 50% on February 27, 2027, provided Ryan Confer continues as a service provider through each date.

Under which plan were the RSUs to Genprex (GNPX) CEO granted?

The RSU award was granted under the Genprex, Inc. 2018 Equity Incentive Plan, as amended and restated effective June 30, 2025.

How are the RSUs for Genprex (GNPX) CEO settled when they vest?

When vested, each restricted stock unit will be paid in one share of Genprex’s common stock, with a $0.001 par value, on a one-to-one basis.

How many Genprex (GNPX) shares does Ryan Confer beneficially own after this RSU grant?

After this reported transaction and the reverse stock split, Ryan Confer beneficially owns 45,661 shares of Genprex common stock.

How did Genprex’s reverse stock split affect the reported share ownership?

The filing notes that the 45,661 shares beneficially owned by Ryan Confer are stated after giving effect to Genprex’s 1-for-50 reverse stock split of common stock that became effective as of October 21, 2025.

What is Ryan Confer’s role and relationship to Genprex (GNPX)?

Ryan Confer is listed as a director and as an officer, serving as President, CEO and CFO of Genprex, Inc.